AstraZeneca (AZN)

AstraZeneca has become the latest major drugmaker to scale back investment in the United Kingdom, pausing a planned £200 million ($271 million) expansion of its Cambridge research site. The move, whic...

Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Brit...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

AstraZeneca PLC (LSE:AZN) may have caught the market's attention last weekend with promising data on its experimental blood pressure treatment, but the follow-up analysis suggests the story is far fro...

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Since last month, AstraZeneca's shares have trounced the S&P 500 index. The drugmaker has an impressive drug portfolio and a deep pipeline, which should continue to drive core EPS growth for the fores...

Among the noise of tariffs, drug pricing reforms, and shifting investor sentiment, AstraZeneca PLC (LSE:AZN) has quietly delivered a clear result: its experimental blood pressure treatment, baxdrostat...

AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a senior company executive said, about a product seen as key to the drugmaker...